Full Name
Dr. Jill Kolesar BCPS, PharmD
Job Title
University Research Professor
Practice/Company Name
University of Kentucky
Speaker Bio
Jill M. Kolesar, Pharm. D., M.S. FCCP, BCPS
Dr. Jill Kolesar is a University Research Professor at the University of Kentucky, the Dr. Michael Karpf Endowed Chair in Precision Medicine and holds administrative positions at the Markey Cancer Center as the Director of the Precision Medicine Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Translational Oncology Program. She is a member of the Graduate Faculty in the College of Pharmacy, a member of the Markey Cancer Center and holds a joint appointment in the Division of Gynecologic Oncology in the College of Medicine.
Dr. Kolesar contributes substantial and sustained professional service to both the National Cancer Institute (NCI) and several pharmacy organizations. Serving on both the Early Phase and Cancer Prevention Central IRBs (CIRBs), multiple NCI study sections, and the Cancer Therapy and Evaluation Program (CTEP) Pharmacology task force and the Investigational Drug Steering Committee. Jill is a board certified Pharmacotherapy Specialist and is a past President of the American College of Clinical Pharmacy (ACCP).
Dr. Kolesar’s research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 500 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $15 million in research funding from the NCI, American Cancer Society and other sources.
Dr. Jill Kolesar is a University Research Professor at the University of Kentucky, the Dr. Michael Karpf Endowed Chair in Precision Medicine and holds administrative positions at the Markey Cancer Center as the Director of the Precision Medicine Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Translational Oncology Program. She is a member of the Graduate Faculty in the College of Pharmacy, a member of the Markey Cancer Center and holds a joint appointment in the Division of Gynecologic Oncology in the College of Medicine.
Dr. Kolesar contributes substantial and sustained professional service to both the National Cancer Institute (NCI) and several pharmacy organizations. Serving on both the Early Phase and Cancer Prevention Central IRBs (CIRBs), multiple NCI study sections, and the Cancer Therapy and Evaluation Program (CTEP) Pharmacology task force and the Investigational Drug Steering Committee. Jill is a board certified Pharmacotherapy Specialist and is a past President of the American College of Clinical Pharmacy (ACCP).
Dr. Kolesar’s research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 500 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $15 million in research funding from the NCI, American Cancer Society and other sources.
Speaking At
